

In the matter of the Canadian Anti-Doping Program;

And in the matter of an anti-doping rule violation by Jeus Mapatac asserted by the Canadian Centre for Ethics in Sport;

File Outcome Summary

Summary

1. The Canadian Centre for Ethics in Sport (CCES) conducted an In-Competition Sample collection session on December 7, 2024, in Calgary, Alberta.
2. Jeus Mapatac ("the Athlete") was selected for Doping Control. The Sample provided by the Athlete, returned an Adverse Analytical Finding (AAF) for SARM RAD140 and SARM Ostarine (S-22), both non-Specified Substances included on the World Anti-Doping Agency's (WADA) 2024 Prohibited List.
3. Following receipt of the CCES's Notice of Charge letter asserting an anti-doping rule violation (ADRV) for the presence and Use of the above-mentioned Prohibited Substances, the Athlete signed an Early Admission and Acceptance of Sanction Form, thereby admitting the ADRV, waiving his right to a hearing and accepting all applicable Consequences.

Jurisdiction

4. The CCES is an independent not-for-profit organization incorporated under the federal laws of Canada that promotes ethical conduct in all aspects of sport in Canada and is responsible for handling the administration of the Canadian Anti-Doping Program (CADP), including providing anti-doping services to national Sport Organizations and their members.
5. As Canada's National Anti-Doping Organization, the CCES is compliant the World Anti-Doping Code ("the Code") and its mandatory International Standards. The CCES has implemented the Code and the International Standards through the CADP, the domestic rules which govern this proceeding. The purpose of the Code and of the CADP is to protect the rights of athletes to fair competition.
6. The Athlete is a member of and participates in the activities of Canada Powerlifting (CANPL). According to CADP Rule 1.3, the CADP provisions apply to all members of and Participants in activities of adopting Sport Organizations. The CADP was issued for adoption by Canadian Sport Organizations on October 26, 2020. CANPL adopted the CADP on October 29, 2020. Therefore, as a Participant in CANPL activities, the Athlete is subject to the CADP.

Doping Control

7. On December 7, 2024, the CCES conducted an In-Competition Sample collection session in Calgary, AB. Testing was conducted as part of the CCES's domestic test distribution plan within the CADP.

8. The Athlete was notified that he had been selected for Doping Control and, together with the Doping Control Officer from the CCES, completed the Sample collection process. The Athlete's Sample code number was 8072889.

Results Management

9. On December 11, 2024, the Athlete's Sample was received for analysis by the INRS Centre Armand-Frappier Santé Biotechnologie ("the INRS") in Laval, QC, a WADA-accredited laboratory.
10. The AAF was reported by the INRS on December 20, 2024. The Certificate of Analysis indicated the presence of SARM RAD140 and SARM Ostarine (S-22).
11. SARM RAD140 and SARM Ostarine (S-22), are classified as non-Specified Substances on WADA's 2024 Prohibited List.
12. On January 21, 2025, the CCES issued to the Athlete a Notification of a potential ADRV for the presence and Use of Prohibited Substances and imposed a Provisional Suspension on the Athlete pursuant to CADP Rule 7.4.1.
13. On January 27, 2025, the Athlete responded to the CCES's Notification letter with their explanation.
14. On February 2, 2025, the Athlete requested the analysis of their B sample.
15. On February 26, 2025, the INRS confirmed the presence of SARM RAD140 and SARM Ostarine (S-22), in the Athlete's B sample.
16. On May 1, 2025, the CCES formally issued a Notice of Charge asserting an ADRV against the Athlete for the presence and Use of Prohibited Substances.
17. In accordance with CADP Rule 10.2.1.1, the standard sanction for a violation involving non-Specified Substances is a four (4) year period of ineligibility.

Confirmation of Violation and Sanction

18. On May 17, 2025, the Athlete signed and submitted to the CCES the Early Admission and the ADRV was confirmed against the Athlete for the presence and Use of the identified Prohibited Substances. In accordance with CADP Rules 10.2.1.1, and 10.8.1, the sanction for this violation is a four (4) year period of Ineligibility with a one (1) year reduction for a total of a three (3) year period of Ineligibility. Therefore, in accordance with CADP Rule 10.13.2.1, the period of Ineligibility commenced on January 21, 2025, the date the Athlete was provisionally suspended, and concludes on January 20, 2028.
19. Further, in accordance with CADP Rules 9, 10.1 and 10.10, any competitive results obtained by the Athlete from date of Sample collection to the date the Athlete was provisionally suspended shall be Disqualified.

20. The CCES now considers this case closed.

Dated at Ottawa, Ontario this 10th day of June 2025.

A handwritten signature in black ink, appearing to be 'KB' followed by a horizontal line.

Kevin Bean
Executive Director, Sport Integrity
CCES